Pulse Biosciences completes enrollment in cardiac ablation study

Pulse Biosciences (PLSE) completed enrollment for its NANOPULSE-AF study, meeting its target of 164 patients across 15 sites. The study aims to assess the safety and effectiveness of its nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Analysts forecast revenue of $38.3M and earnings of $4.8M by 2029, with significant growth and earnings swing expected. The trial's outcomes will influence regulatory, reimbursement, and commercialization decisions.

Pulse Biosciences (PLSE) completed enrollment of 164 patients in its NANOPULSE-AF study, three months ahead of schedule. The study evaluates the nPulse Cardiac Catheter System for drug-resistant atrial fibrillation. Primary endpoints will be assessed at 6 and 12 months post-ablation, with updates planned as follow-ups conclude.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Achieves Enrollment Target in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse ™ Cardiac Catheter System for Atrial Fibrillation Treatment 164 evaluable patients enrolled across 15 clinical sites HAYWARD, California , October 7, 2026 — Puls

Canaccord raised its price target on Pulse Biosciences (PLSE) to $58 from $43, maintaining a Buy rating. The stock has surged 87.5% since Canaccord initiated coverage and 268% year-to-date, with a $3.6B market cap. The firm cited the company's nanosecond pulse field ablation platform and clinical progress. Pulse also announced an equity distribution agreement with Mizuho Securities for up to $85M in common stock sales.

PULSE BIOSCIENCES, INC. (PLSE) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse ™ Vybrance ™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules Completed 100 patient enrollment across three U.S. sites; first patient enrolled completed

Pulse Biosciences (PLSE) stock rose 8.3% after Freedom Capital analyst Keith Hinton initiated coverage with a Buy rating and $73 price target. Hinton highlighted the company's nsPFA technology, strong balance sheet, and potential for acquisition. The NANOPULSE-AF trial is on track, with results expected in Q2 2027. Insider buying and trial progress have boosted investor confidence.